Showing 91-100 of 169 results for "".
- Literature Review Examines Need for Better Treatment of PsO in Skin of Colorhttps://practicaldermatology.com/news/Literature-Review-Examines-Need-Better-Treatment-PsO-Skin-Color/2471097/A recent literature review on psoriasis in patients with skin of color (SOC) “invokes an important call to action by the [International Psoriasis Council],” its authors wrote I the International Journal of Dermatology. “Education on diagnosing and treating psoriasis in all populations, inc
- Lecture Updates on Abrocitinib, Povorcitinib for PNhttps://practicaldermatology.com/news/lecture-updates-abrocitinib-povorcitinib-pn/2468486/Dr. Shawn Kwatra gets goosebumps when he thinks about having two approved biologics for prurigo nodularis, (PN) he said during a session at the 44th Annual Fall Clinical Dermatology Conference. “I have to pinch myself,” Dr. Kwatra said during “Making the Connection Between Prurigo Nodulari
- Dermavant Publishes ADORING 1 & ADORING 2 Phase 3 Trial Results for Vtama Cream for ADhttps://practicaldermatology.com/news/dermavant-publishes-adoring-1-adoring-2-phase-3-trial-results-vtama-cream-ad/2463173/Dermavant Sciences announced that the data from ADORING 1 and ADORING 2 phase 3 trials of Vtama (tapinarof) cream 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology. Vtama cream i
- Revance's Erica Jordan Promoted to CCOhttps://practicaldermatology.com/news/revances-erica-jordan-promoted-to-coo/2462124/Erica Jordan is now Revance Therapeutics, Inc.’s Chief Commercial Officer (CCO), Aesthetics. “Given the importance of the DAXXIFY launch, I’m excited to elevate Erica to the position of Chief Commercial Officer, Aesthetics reporting directly to me. Having wo
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers i
- Oro Health, Dermago Unveil Consumer Version of its AI-powered Dermatology Assessment and Recommendation Toolhttps://practicaldermatology.com/news/oro-health-dermago-unveil-consumer-version-of-its-ai-powered-dermatology-assessment-and-recommendation-tool/2461822/Oro Health and Dermago are unveiling the public version of DermSmart, a tool designed to classify skin types and minor skin conditions. This new AI-driven version offers patients the ability to upload pictures of their skin condition, ask questions and interact with the tool i
- Take That, Melanoma: Universal Cancer Vaccine Boosts Overall Survivalhttps://practicaldermatology.com/news/take-that-melanoma-universal-cancer-vaccine-boosts-overall-survival/2461790/Ultimovacs’ UV1 universal cancer vaccine boosted overall survival in malignant melanoma, according to a three-year update from a Phase I clinical trial. UV1 is a universal cancer vaccine designed to induce a specific T cell response against telomerase. The U.S. Food and Drug Admin
- Dr. Michele L. Ramien Takes the Helm as President of the Canadian Dermatology Associationhttps://practicaldermatology.com/news/dr-michele-l-ramien-takes-the-helm-as-president-of-the-canadian-dermatology-association/2461789/Dr. Michele L. Ramien is the new president of The Canadian Dermatology Association (CDA). “I want to increase engagement amongst our members by re-imagining how our community interacts so that - united - we are ready to accomplish all the work we need to do,” says Dr.
- Highly Trafficked Roads Up AD Risk in Kids, Teenshttps://practicaldermatology.com/news/highly-trafficked-roads-up-ad-risk-in-kids-teens/2461772/Traffic-related air pollution may increase children and teen’s risk for atopic dermatitis report researchers at National Jewish Health in Denver, Colo. For the study, researchers reviewed charts of patients 0-18 years of age who had been seen at National Jewish Health i
- Sol-Gel, Searchlight Pharma Partner to Commercialize TWYNEO and EPSOLAY in Canadahttps://practicaldermatology.com/news/sol-gel-searchlight-pharma-partner-to-commercialize-twyneo-and-epsolay-in-canada/2461764/Israel’s Sol-Gel Technologies, Ltd. and Searchlight Pharma Inc. have signed exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. Both products recently launched in the U.S., and Searchlight is to commercialize in Canada over a fifteen-year term that i